Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma:its efficacy still needs to be determined

查看全文 作　　者：Heming [1]Li;Xiangjun [2]Hao;Tao [1]Han 机构地区：[1]Department of Medical Oncology,the First Hospital of China Medical University,Shenyang,China;[2]Department of Clinical Pharmacy,Shenyang Pharmaceutical University,Shenyang,China 出　　处：《Hepatobiliary Surgery and Nutrition》索引2023年第12卷第3期,共4页 摘　　要：The current landscape for advanced hepatocellular carcinoma(HCC)has evolved drastically in recent years,with the ever-increasing development of novel standard first-line therapeutic strategies(e.g.,the combination of atezolizumab and bevacizumab)and the approval of several new agents for second line strategies,such as regorafenib and cabozantinib(1,2).Although a large number of treatment options are available for advanced HCC patients,multikinase inhibitor(MKI)-based immunotherapy doublet has become notably complex,especially after the publication of the COSMIC-312 trial(3).This study evaluated the efficacy and safety of cabozantinib combined with atezolizumab versus sorafenib as the first-line treatment of patients with advanced HCC.Although the primary endpoint of progression-free survival(PFS)was significantly improved with treatment using cabozantinib combined with atezolizumab compared with sorafenib in the COSMIC-312 trial,the overall survival(OS)did not improve,and the response rate was lower than expected(3).Nevertheless,this was a crucial randomized controlled trial(RCT)evaluating the efficacy of MKI-based immunotherapy doublet as the first-line systemic therapy for advanced HCC,paving the way for future investigations to determine the underlying mechanism of these connections.We have several concerns with the interpretation of this study. 关 键 词：Advanced hepatocellular carcinoma(advanced HCC) multikinase inhibitor(MKI) IMMUNOTHERAPY hepatitis B virus(HBV) clinical trial